| Schedule of Segment Reporting |
The following table presents selected financial information about the Company's single operating segment for the three and six months ended June 30, 2026 and 2025 (in thousands): | | | | | | | | | | | | | | | | | | | | | | | | | Three Months Ended
June 30, | | Six Months Ended June 30, | | 2026 | | 2025 | | 2026 | | 2025 | | Program-specific expenses: | | | | | | | | | Ulixacaltamide | $ | 13,299 | | | $ | 18,385 | | | $ | 32,402 | | | $ | 41,898 | | | Vormatrigine | 12,878 | | | 17,957 | | | 33,372 | | | 31,690 | | | Relutrigine | 13,979 | | | 10,509 | | | 26,833 | | | 15,886 | | | Elsunersen | 8,141 | | | 1,317 | | | 11,338 | | | 2,078 | | | Other early stage assets | 5,471 | | | 1,417 | | | 8,713 | | | 2,522 | | | Personnel-related expenses | 18,943 | | | 11,913 | | | 36,673 | | | 24,943 | | | Stock-based compensation expense | 11,309 | | | 7,770 | | | 28,421 | | | 16,556 | | | Depreciation expense | 33 | | | 46 | | | 72 | | | 93 | | Other segment expenses(a) | 12,851 | | | 6,753 | | | 24,940 | | | 15,129 | | | Other income, net | 13,184 | | | 4,940 | | | 26,483 | | | 10,372 | | | Consolidated net loss | $ | (83,720) | | | $ | (71,127) | | | $ | (176,281) | | | $ | (140,423) | |
(a) Other segment expenses includes research and development and general and administrative costs not attributable to a specific program.
|